Literature DB >> 8023696

Benzodiazepines in the treatment of catatonic syndrome.

G S Ungvari1, C M Leung, M K Wong, J Lau.   

Abstract

During a 5-month period, 18 (8%) of 212 patients admitted to a psychiatric unit affiliated to a teaching hospital were found to have a catatonic syndrome associated with various nonorganic mental disorders. Signs and symptoms of motor retardation predominated the clinical presentations. In the course of a prospective, open study, all 18 patients were challenged by a small dose of oral lorazepam or intramuscular diazepam. Catatonic signs and symptoms in 2 patients showed an immediate, complete, and sustained response to the medication. The remaining 16 patients were maintained on 1 of the 2 benzodiazepines for the next 48 h when their motor status was re-evaluated. Significant clinical improvement was detected in all but 2 patients. However, 9 patients needed electroconvulsive treatment to achieve further improvement. Short-term benzodiazepine administration proved to be a safe and effective treatment of the catatonic syndrome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8023696     DOI: 10.1111/j.1600-0447.1994.tb01515.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  25 in total

1.  Catatonia in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.

Authors:  Andrew Francis; Max Fink; Francisco Appiani; Aksel Bertelsen; Tom G Bolwig; Peter Bräunig; Stanley N Caroff; Brendan T Carroll; Andrea Eugenio Cavanna; David Cohen; Olivier Cottencin; Manuel J Cuesta; Jessica Daniels; Dirk Dhossche; Gregory L Fricchione; Gabor Gazdag; Neera Ghaziuddin; David Healy; Donald Klein; Stephanie Krüger; Joseph W Y Lee; Stephan C Mann; Michael Mazurek; W Vaughn McCall; William W McDaniel; Georg Northoff; Victor Peralta; Georgios Petrides; Patricia Rosebush; Teresa A Rummans; Edward Shorter; Kazumasa Suzuki; Pierre Thomas; Guillaume Vaiva; Lee Wachtel
Journal:  J ECT       Date:  2010-12       Impact factor: 3.635

2.  Going Back to Kahlbaum's Psychomotor (and GABAergic) Origins: Is Catatonia More Than Just a Motor and Dopaminergic Syndrome?

Authors:  Dusan Hirjak; Katharina M Kubera; R Christian Wolf; Georg Northoff
Journal:  Schizophr Bull       Date:  2020-02-26       Impact factor: 9.306

3.  Response rate of catatonia to electroconvulsive therapy and its clinical correlates.

Authors:  Dhanya Raveendranathan; Janardhanan C Narayanaswamy; Senthil V Reddi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-30       Impact factor: 5.270

Review 4.  Electroconvulsive therapy in catatonic patients: Efficacy and predictors of response.

Authors:  Federica Luchini; Pierpaolo Medda; Michela Giorgi Mariani; Mauro Mauri; Cristina Toni; Giulio Perugi
Journal:  World J Psychiatry       Date:  2015-06-22

5.  Organic catatonia: a review.

Authors:  N Ahuja
Journal:  Indian J Psychiatry       Date:  2000-10       Impact factor: 1.759

Review 6.  The catatonia conundrum: evidence of psychomotor phenomena as a symptom dimension in psychotic disorders.

Authors:  Gabor S Ungvari; Stanley N Caroff; Jozsef Gerevich
Journal:  Schizophr Bull       Date:  2009-09-23       Impact factor: 9.306

Review 7.  Catatonia and its treatment.

Authors:  Patricia I Rosebush; Michael F Mazurek
Journal:  Schizophr Bull       Date:  2009-12-07       Impact factor: 9.306

8.  Catatonic syndrome : treatment response to Lorazepam.

Authors:  H Payee; R Chandrasekaran; G V Raju
Journal:  Indian J Psychiatry       Date:  1999-01       Impact factor: 1.759

9.  Catatonia: short-term response to lorazepam and dopaminergic metabolism.

Authors:  G Northoff; J Wenke; L Demisch; J Eckert; B Gille; B Pflug
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

10.  Moderate clinical improvement with maintenance ECT in a 17-year-old boy with intractable catatonic schizophrenia.

Authors:  Angèle Consoli; Valérie Boulicot; Françoise Cornic; Philippe Fossati; Martine Barbeau; David Cohen
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-01-20       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.